Skip to content
Trial Eligibility
Menu

Multiple Sclerosis Clinical Trials Recruiting in the US

140 studies for Multiple Sclerosis are recruiting at 612 US sites, according to ClinicalTrials.gov data processed .

Multiple sclerosis (MS) is a long-term disease of the brain and spinal cord in which the immune system damages the protective covering of nerves.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Top Multiple Sclerosis studies by number of US sites

Showing 30 studies, most US recruiting sites first.
  1. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

    NCT06433752

    • Observational
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    109 US recruiting sites
  2. Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    NCT06846281

    • Phase 3
    • Ages 40 to 70 years
    • Sex: All
    Recruiting sites
    43 US recruiting sites
  3. A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    NCT07225504

    • Phase 3
    • Ages 18 to 65 years
    • Sex: All
    Recruiting sites
    42 US recruiting sites
  4. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    NCT03816345

    • Phase 1
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    40 US recruiting sites
  5. Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    NCT05877963

    • Phase 3
    • Ages 18 to 65 years
    • Sex: All
    Recruiting sites
    39 US recruiting sites
  6. Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

    NCT07325292

    • Phase 3
    • Ages 18 to 60 years
    • Sex: All
    Recruiting sites
    34 US recruiting sites
  7. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    NCT07002034

    • Phase 2
    • Ages 18 to 80 years
    • Sex: All
    Recruiting sites
    32 US recruiting sites
  8. A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

    NCT07299019

    • Phase 3
    • Ages 18 to 60 years
    • Sex: All
    Recruiting sites
    25 US recruiting sites
  9. Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

    NCT04047628

    • Phase 3
    • Ages 18 to 55 years
    • Sex: All
    Recruiting sites
    19 US recruiting sites
  10. A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

    NCT07067463

    • Phase 3
    • Ages 18 to 60 years
    • Sex: All
    Recruiting sites
    17 US recruiting sites
  11. A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

    NCT06782490

    • Phase 2
    • Ages 18 to 70 years
    • Sex: All
    Recruiting sites
    14 US recruiting sites
  12. The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

    NCT06796504

    • Interventional
    • Ages 22 to 60 years
    • Sex: All
    Recruiting sites
    9 US recruiting sites
  13. A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

    NCT06680037

    • Phase 1
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    8 US recruiting sites
  14. Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

    NCT07477639

    • Phase 1/2
    • Ages 18 to 65 years
    • Sex: All
    Recruiting sites
    8 US recruiting sites
  15. A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

    NCT06735248

    • Phase 2
    • Ages 18 to 55 years
    • Sex: All
    Recruiting sites
    6 US recruiting sites
  16. Care in Multiple Sclerosis (MS)

    NCT07011914

    • Observational
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    6 US recruiting sites
  17. An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

    NCT07224373

    • Phase 1
    • Ages 18 to 60 years
    • Sex: All
    Recruiting sites
    6 US recruiting sites
  18. Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

    NCT06408259

    • Phase 3
    • Ages 10 to 17 years
    • Sex: All
    Recruiting sites
    5 US recruiting sites
  19. A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

    NCT07304154

    • Phase 1
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    5 US recruiting sites
  20. A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

    NCT07609719

    • Phase 4
    • Ages 18 to 65 years
    • Sex: All
    Recruiting sites
    4 US recruiting sites
  21. Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research

    NCT07623668

    • Phase 3
    • Ages 18 to 50 years
    • Sex: All
    Recruiting sites
    4 US recruiting sites
  22. Genes and Environment in Multiple Sclerosis

    NCT01353547

    • Observational
    • Ages 18 years and older
    • Sex: All
    • Accepts healthy volunteers
    Recruiting sites
    3 US recruiting sites
  23. Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

    NCT05395624

    • Phase 1/2
    • Ages 18 to 80 years
    • Sex: All
    • Accepts healthy volunteers
    Recruiting sites
    3 US recruiting sites
  24. Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

    NCT06529406

    • Phase 4
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    3 US recruiting sites
  25. Multiple Sclerosis Implementation Network (Registry)

    NCT07415824

    • Observational
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    3 US recruiting sites
  26. A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

    NCT07840326

    • Phase 2
    • Ages 18 to 70 years
    • Sex: All
    Recruiting sites
    3 US recruiting sites
  27. Neurologic Stem Cell Treatment Study

    NCT02795052

    • Interventional
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    2 US recruiting sites
  28. A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring

    NCT05170126

    • Observational
    • Ages Any age
    • Sex: Female
    Recruiting sites
    2 US recruiting sites
  29. Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

    NCT05658497

    • Observational
    • Ages Any age
    • Sex: Female
    Recruiting sites
    2 US recruiting sites
  30. High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis

    NCT05735691

    • Interventional
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    2 US recruiting sites

By city

Multiple Sclerosis clinical trials by city

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Multiple Sclerosis clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.